Regenxbio and Clearside Biomedical announced an option and license agreement that will give Regenxbio exclusive worldwide rights to Clearside’s SCS Microinjector for the delivery of RGX-314 to the suprachoroidal space.
RGX-314 includes the NAV AAV8 vector encoding an antibody fragment to inhibit VEGF. Regenxbio is evaluating RGX-314 using the SCS Microinjector for in-office, nonsurgical delivery to the suprachoroidal space while also advancing its subretinal delivery program for the treatment of wet age-related macular degeneration and diabetic retinopathy, according to a press release.
“We
Uncategorized